Lv3
370 积分 2023-08-28 加入
Sixty Years of Hemodynamic Pharmacology in Obstructive Hypertrophic Cardiomyopathy
1天前
已完结
Hypertrophic cardiomyopathy management: a systematic review of the clinical practice guidelines and recommendations
3天前
已完结
New insights in efficacy of different enzyme replacement therapy dosages in Fabry disease: Switch studies data following agalsidase beta shortage
4天前
已完结
Hypertrophic cardiomyopathy: investigational drugs inhibiting myosin and upcoming agents
17天前
已完结
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
23天前
已完结
Reduced incidence of stroke in patients with Fabry disease treated with agalsidase beta: A matched analysis from the Fabry Registry
1个月前
已完结
Cardiac Myosin Inhibition in Obstructive Hypertrophic Cardiomyopathy
1个月前
已完结
Diagnosis and Treatment of Obstructive Hypertrophic Cardiomyopathy
1个月前
已完结
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial
1个月前
已完结
Global cardiac alterations detected by speckle-tracking echocardiography in Fabry disease: left ventricular, right ventricular, and left atrial dysfunction are common and linked to worse symptomatic status
1个月前
已完结
皖公网安备34019202002308
